New first-line treatment combinations for chronic lymphocytic leukemia (CLL)
Official title: Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials
Funded at Mayo Clinic Rochester · NIH-11164692 · Data updated 2026-11-12
This work compares different drug combinations—including ibrutinib, venetoclax, and obinutuzumab—for people with previously untreated CLL, with trials for both younger and older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 8, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $124,230 |
| NIH project number | 5R50CA291823-02 |
| Project ID | NIH-11164692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with newly diagnosed, previously untreated CLL, with some trial arms specifically enrolling adults aged 65 and older and others open to younger adults per protocol.
✕Less likely to help
People with relapsed or refractory CLL, other types of leukemia, or who are medically ineligible for the trial treatments would likely not benefit directly from these specific trials.
What this research studies
This effort follows people with newly diagnosed, untreated CLL who receive one of two frontline drug combinations to see which works better for different patients. One trial focuses on older adults (age 65 and up) while another enrolls younger patients, and participants are randomly assigned to treatment arms. Doctors will track clinical outcomes and collect blood and biomarker samples to learn who benefits most and why. Results will be used to write reports and to design the next national frontline treatment protocol.
Why it matters
Potential benefit: If successful, this could identify frontline drug combinations that produce deeper and longer remissions for people with untreated CLL.
How similar studies have gone: Targeted drugs such as ibrutinib, venetoclax, and obinutuzumab have already improved outcomes in CLL, but large randomized comparisons of these exact combinations are still being completed.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Parikh, Sameer Ashok — Mayo Clinic Rochester
- Study coordinator: Parikh, Sameer Ashok
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.